August 2023 Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma – Cancers 2021
August 2023 Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma – Blood Adv. 2020
August 2023 Development of a Targeted MS Serum Assay To Quantify M‑Protein in the Presence of Therapeutic Monoclonal Antibodies – J Proteome Res. 2018
June 2023 MRD Monitoring by Targeted Mass Spectrometry Allows Early Relapse Detection in MM – Blood 2022
June 2023 An ultra-sensitive method for sequencing and monitoring M-protein in peripheral blood – EMN 2023
June 2023 Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for MRD Monitoring in MM – Clin Chem. 2021
June 2023 Mass Spectrometry for Identification, Monitoring, and MRD Detection of M-Proteins – Clin Chem. 2020
June 2023 Multiple Myeloma MRD Detection: Targeted Mass Spectrometry in Blood vs Next-Generation Sequencing in Bone Marrow – Clin Chem. 2021
June 2023 Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry – Blood Cancer J. 2023
